IS050770A - CRF2 viðtakaverkar og notkun þeirra í meðferð - Google Patents

CRF2 viðtakaverkar og notkun þeirra í meðferð

Info

Publication number
IS050770A
IS050770A IS050770A IS050770A IS050770A IS 050770 A IS050770 A IS 050770A IS 050770 A IS050770 A IS 050770A IS 050770 A IS050770 A IS 050770A IS 050770 A IS050770 A IS 050770A
Authority
IS
Iceland
Prior art keywords
therapy
receptor antagonists
crf2 receptor
crf2
antagonists
Prior art date
Application number
IS050770A
Other languages
English (en)
Inventor
Philip Janiak
Marie-Laure Ozoux
Daniela Roversi
Elisabetta Bianchi
Martina Tripepi
Alessia Santoprete
Original Assignee
Corteria Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corteria Pharmaceuticals filed Critical Corteria Pharmaceuticals
Publication of IS050770A publication Critical patent/IS050770A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
IS050770A 2022-02-23 2024-09-18 CRF2 viðtakaverkar og notkun þeirra í meðferð IS050770A (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22158188.7A EP4234574A1 (en) 2022-02-23 2022-02-23 Crf2 receptor agonists and their use in therapy

Publications (1)

Publication Number Publication Date
IS050770A true IS050770A (is) 2024-10-15

Family

ID=80819682

Family Applications (1)

Application Number Title Priority Date Filing Date
IS050770A IS050770A (is) 2022-02-23 2024-09-18 CRF2 viðtakaverkar og notkun þeirra í meðferð

Country Status (15)

Country Link
US (1) US20260001928A1 (is)
EP (3) EP4234574A1 (is)
JP (1) JP2025508820A (is)
KR (1) KR20240153565A (is)
CN (1) CN118843638A (is)
AU (1) AU2023224327A1 (is)
CA (1) CA3247142A1 (is)
ES (1) ES3063881T3 (is)
HR (1) HRP20260115T1 (is)
IL (1) IL314055A (is)
IS (1) IS050770A (is)
MX (1) MX2024010296A (is)
PL (1) PL4482578T3 (is)
WO (1) WO2023161229A1 (is)
ZA (1) ZA202406196B (is)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260089954A (ko) * 2023-11-17 2026-06-16 구브라 에이/에스 hCRHR2 선택적 폴리펩타이드
WO2026064495A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2026064486A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114437A2 (en) * 2006-10-16 2009-11-11 ConjuChem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
US12679878B2 (en) * 2020-08-19 2026-07-14 Sanofi CRF2 receptor agonists and their use in therapy

Also Published As

Publication number Publication date
EP4482578C0 (en) 2025-12-24
CA3247142A1 (en) 2023-08-31
EP4482578A1 (en) 2025-01-01
CN118843638A (zh) 2024-10-25
IL314055A (en) 2024-09-01
WO2023161229A1 (en) 2023-08-31
AU2023224327A1 (en) 2024-08-29
EP4482578B1 (en) 2025-12-24
EP4781998A2 (en) 2026-07-29
MX2024010296A (es) 2024-09-18
JP2025508820A (ja) 2025-04-10
KR20240153565A (ko) 2024-10-23
HRP20260115T1 (hr) 2026-03-13
ZA202406196B (en) 2025-03-26
ES3063881T3 (en) 2026-04-21
EP4234574A1 (en) 2023-08-30
PL4482578T3 (pl) 2026-03-16
US20260001928A1 (en) 2026-01-01

Similar Documents

Publication Publication Date Title
IS3063B (is) CRF2 viðtakaverkar og notkun þeirra í meðferð
DK4058445T3 (da) Glp-1-receptoragonist og anvendelse deraf
HRP20260115T1 (hr) Agonisti crf2 receptora i njihova primjena u terapiji
DK4219487T3 (da) Glp-1-receptoragonister og anvendelse heraf
DK3866376T3 (da) Fremgangsmåder med fysisk lag og mac-lag i en trådløs indretning
IS8190A (is) Ný P2X7 viðtakamótlyf og notkun þeirra
IL286248A (en) Tyk2 inhibitors and uses thereof
DK4497438T3 (da) Tricykliske parp1-hæmmere og deres anvendelse
IS8329A (is) Kínólínafleiður og notkun þeirra í meðferð
SI3746467T1 (sl) Modificirani lipidirani peptidi relaksina z verigo B in njihova terapevtska uporaba
EP4442700A4 (en) Pharmaceutical composition of glp-1 and gip receptor dual agonist and use thereof
CO6280470A2 (es) Bis-piridilpiridonas como antaginistas del receptor 1 de la hormona concentradora de la melanina
EP4190802A4 (en) NOVEL CELL PENETRATION PEPTIDE AND ASSOCIATED USE
IL321519A (en) Multivalent and multispecific cytokine antagonists
DK1831149T3 (da) Hidtil ukendte ligander, der modulerer rar-receptorer, og anvendelse deraf i human medicin og i kosmetik
DK4255563T3 (da) 5´-o-phenylacetyluridin og terapeutisk anvendelse
IL284981A (en) Semaphorin-4d antagonists for use in cancer therapy
EP4326771A4 (en) CHIMERIC CYTOKINE RECEPTORS AND THEIR USES IN CELLULAR THERAPIES
IL280831A (en) Combination therapy with C-C antagonists such as cytokine receptor 4 (CCR4) and one or more immune checkpoint inhibitors
ITRM20040058A1 (it) Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
EP4380560A4 (en) LPAR1 ANTAGONISTS AND THEIR USES
IL319234A (en) Pyrazolylsulfonamide compounds and their use in therapy
EP3837008C0 (en) Substituted Benzamides and Their Use in Therapy
EP4259644A4 (en) Immunocytokine for activating human il-10ra receptor and use thereof
NO20055515D0 (no) 7-azaindoler og deres anvendelse som terapeutiske midler